Black Diamond Therapeutics nabs $85 mln Series B

Black Diamond Therapeutics Inc, a biotechnology company developing next-generation precision medicines for cancer, has closed $85 million in Series B financing. New Enterprise Associates and RA Capital Management led the round with participation from NexTech Invest, The Invus Group, Perceptive Advisors and Versant Ventures.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!